Asthma: SERETIDE is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate.
This may include: Patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids.
Patients who are symptomatic on current inhaled corticosteroid therapy.
Patients on regular bronchodilator therapy who require inhaled corticosteroids.
Chronic Obstructive Pulmonary Disease (COPD): Accuhaler: SERETIDE ACCUHALER 50mcg/250mcg and SERETIDE ACCUHALER 50mcg/500mcg are indicated for the maintenance treatment of COPD, including emphysema and chronic bronchitis in patients where the use of a combination product is considered appropriate.
Inhaler: SERETIDE Inhaler 25/125 and SERETIDE Inhaler 25/250 are indicated for the symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. SERETIDE is not indicated for the initiation of bronchodilator therapy in COPD.